The following is a summary of the STERIS Plc (STE) Q4 2024 Earnings Call Transcript:
Financial Performance:
STERIS Plc reported total Q4 revenue growth of 10%, with adjusted earnings per diluted share at $2.58.
Full year revenue growth reached 12%, with adjusted earnings per share at $8.83.
Gross margin for the quarter declined to 42.6% while EBIT margin decreased to 23.7%.
Capital expenditures totaled $360 million while the total debt sat at $3.2 billion, with a debt-to-EBITDA ratio of 2.1.
Free cash flow was $620 million for the fiscal year 2024.
Business Progress:
The Healthcare segment achieved 13% constant currency organic revenue growth, showing continuous progress.
They expect growth in AST, Healthcare, and Life Sciences segments in the upcoming fiscal year.
STERIS provided FY 2025 projections, expecting a 6.5% to 7.5% increase in as-reported revenue.
A targeted restructuring plan is announced, which includes the restructuring of the Healthcare Surgical Capital business in Europe and other actions.
The company decided to divest two businesses during the year, including the Dental segment.
More details: Steris PLC IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.